Necrotizing Fasciitis

Clinical Snapshot

Necrotizing fasciitis is a rapidly progressive infection of fascia and surrounding soft tissue that causes tissue necrosis and systemic toxicity. It is a surgical emergency. Antibiotics are essential but are supportive to source control; survival depends on immediate recognition and aggressive debridement.^[1] The teaching rule is absolute: when necrotizing infection is suspected, do not "try oral antibiotics and reassess tomorrow."

Recognize the Condition

Extensive erythema and early necrosis of the left leg in necrotizing fasciitis

Necrotizing fasciitis of the leg — extensive erythema and necrosis on presentation; this is a surgical emergency, not an antibiotic-first diagnosis. (Smuszkiewicz, Trojanowska, Tomczak, CC BY 2.0, Wikimedia Commons)

Severe pain out of proportion to visible skin findings.
Rapid progression over hours.
Dusky, grey, violaceous, or necrotic skin.
Bullae, anesthesia/numbness, crepitus (subcutaneous gas), or thin foul drainage.
Systemic toxicity, confusion, hypotension, or organ dysfunction.
Early disease may have deceptively mild erythema — do not let a benign-looking surface mislead the assessment.

Risk Factors

Recent trauma, surgery, injection, or wound.
Diabetes, vascular disease, obesity, or immunosuppression.
Injection drug use.
Water exposure for Vibrio/Aeromonas-type infections.
Abdominal/perineal source for polymicrobial/Fournier gangrene.
However, invasive group A streptococcal disease can occur without major comorbidity — do not exclude the diagnosis based on an otherwise-healthy patient.

Red Flags & Refer

Every suspected case is an emergency — any of the following requires immediate emergency transfer and surgical assessment, without waiting for imaging or a trial of therapy:

Severe pain out of proportion.
Rapid spread.
Bullae.
Necrosis.
Crepitus.
Skin anesthesia.
Hemodynamic instability.
Systemic toxicity.

Assessment & Diagnosis

Diagnosis is primarily clinical and operative. Laboratory scores and imaging can support assessment but must never delay surgery when suspicion is high. Obtain blood cultures and deep operative cultures when feasible — superficial swabs are insufficient. Surgical exploration confirms fascial necrosis and provides source control.^[2]

The four necrotizing fasciitis types

Type I

Polymicrobial aerobic/anaerobic infection.

Type II

Often group A streptococcus, sometimes with S. aureus.

Type III

Clostridial or gram-negative organisms such as Vibrio, typically after relevant water exposure.

Type IV

Fungal necrotizing infection, mainly in profoundly immunocompromised hosts.

Treatment Targets

Immediate surgical source control.
Broad empiric antimicrobial coverage within the emergency resuscitation pathway.
Hemodynamic stabilization and organ support.
Narrow therapy to operative culture results once adequate coverage is established.

Choose Initial Treatment

Direct treatment rule

Immediate surgery + broad IV antibiotics, simultaneously — neither waits for the other.

Broad empiric backbone

Piperacillin/tazobactam OR meropenem, plus an MRSA-active agent (vancomycin).

When group A streptococcus or clostridial toxin-mediated disease is suspected

Add clindamycin for toxin suppression.

Once group A streptococcus is confirmed

Narrow to penicillin G + clindamycin.

Non-Pharmacologic Treatment

Immediate aggressive surgical debridement is the definitive treatment.
Repeat operative exploration/debridement until all necrotic tissue is removed.
ICU-level fluid, vasopressor, and organ support as needed.
Wound reconstruction occurs only after infection is controlled.
Invasive group A streptococcal disease requires public-health notification and assessment of close contacts per current public-health guidance.^[3]

Pharmacologic Treatment Options

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Piperacillin/tazobactam Preferred	Broad empiric backbone for Type I/polymicrobial infection	3.375 g IV Q6H (institutional severe-infection protocols may use 4.5 g Q6H)	Hypersensitivity, GI effects, cytopenias, renal/electrolyte effects	1st-line broad empiric agent pending operative cultures.
Meropenem Alternative	Broad empiric alternative, resistant Gram-negative concern	500 mg IV Q6H (severe-infection dosing per institutional/ID protocol)	GI effects, hypersensitivity; markedly lowers valproate levels	Reserve-listed — use only when resistance established or alternatives unsuitable.<cite data-reference-id="a1916f47-12cd-4b78-b846-3e3020c0a76d"></cite>
Clindamycin Preferred	Toxin suppression, added to the beta-lactam backbone	600-900 mg IV Q8H	C. difficile infection risk; hepatic considerations	Add whenever GAS or clostridial necrotizing infection is suspected.
Penicillin G Preferred	Definitive therapy once GAS confirmed, combined with clindamycin	2-4 million units IV Q4-6H (severe-infection dosing per protocol)	Hypersensitivity; electrolyte load at high doses	Narrow to this once culture confirms group A streptococcus.
Vancomycin Preferred	Empiric MRSA coverage until cultures define therapy	Weight-based IV dosing with institutional AUC monitoring	Nephrotoxicity, infusion reaction	Add to the broad backbone until MRSA is excluded.

Special Populations

Pregnancy

Maternal life-saving surgery and broad IV antimicrobials take priority. Choose pregnancy-compatible agents where alternatives are equally effective, but do not delay definitive treatment for that reason.

Water exposure

Salt/brackish-water exposure raises concern for Vibrio; freshwater exposure raises concern for Aeromonas. Obtain infectious-diseases input immediately for additional Gram-negative coverage.

Fournier gangrene

Perineal necrotizing infection requires immediate urologic/general-surgical source control plus broad polymicrobial antibiotics.

Monitoring & Follow-Up

Monitoring is continuous in hospital/ICU: hemodynamics, lactate/organ function, wound progression, operative findings, renal function, and antimicrobial toxicity. Lack of stabilization after initial debridement is a trigger for immediate repeat surgical assessment, not simply broader antibiotics.

Treatment Failure / Next Step

Assume source control is incomplete until proven otherwise.
Return urgently to the operating room when necrosis/progression continues.
Review operative cultures and susceptibility.
Assess for a missed anatomical compartment or ongoing ischemia.
Optimize antimicrobial exposure with infectious-diseases/pharmacy support and organ-function-based dosing.

Common Errors to Avoid

Waiting for CT/MRI before calling surgery when the clinical picture is convincing.
Trying oral antibiotics first.
Treating antibiotics as the definitive therapy instead of debridement.
Omitting clindamycin in suspected invasive GAS/clostridial disease.
Using a narrow regimen before operative cultures clarify a life-threatening polymicrobial infection.

Clinical Decision Algorithm

Algorithm A — Recognition and immediate action

Skin/soft-tissue infection with severe pain out of proportion, rapid progression, dusky/grey skin, bullae, necrosis, crepitus, numbness, or systemic toxicity

NECROTIZING INFECTION UNTIL PROVEN OTHERWISE

Immediate emergency transfer + surgical consultation — do not delay for imaging or response to antibiotics

Obtain blood/operative cultures if this does not delay surgery; start broad IV antibiotics immediately

Urgent operative exploration and aggressive debridement; repeat debridement as required

Algorithm B — Empiric antimicrobial branch

Necrotizing infection: subtype/pathogen not yet known

Broad Gram-positive + MRSA + Gram-negative + anaerobic coverage: piperacillin/tazobactam OR meropenem, plus vancomycin

GAS / clostridial infection suspected

Add clindamycin for toxin suppression; once GAS confirmed, narrow beta-lactam to penicillin G + clindamycin

Polymicrobial / resistant Gram-negative risk

Continue broad beta-lactam backbone; tailor to operative cultures and infectious-diseases guidance

Drug Tables

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Broad empiric backbone

Drug	Dosage	Adverse effects	Comments
Piperacillin/tazobactam	Adults: 3.375 g IV Q6H (institutional severe-infection protocols may use 4.5 g Q6H) Children: 240-300 mg/kg/day (piperacillin component) divided Q6-8H IV (max 16 g/day)	Hypersensitivity, GI effects, cytopenias, renal/electrolyte effects	Renal adjustment required.
Meropenem	Adults: 500 mg IV Q6H (severe-infection dosing per institutional/ID protocol) Children: 10 mg/kg Q8H IV (max 500 mg/dose); severe-infection protocols may dose more frequently	GI effects, hypersensitivity; markedly lowers valproate levels	Reserve-listed alternative.<cite data-reference-id="a1916f47-12cd-4b78-b846-3e3020c0a76d"></cite>

Toxin suppression and definitive GAS therapy

Drug	Dosage	Adverse effects	Comments
Clindamycin	Adults: 600-900 mg IV Q8H Children: 25-40 mg/kg/day divided Q8H IV (max 900 mg/dose in severe invasive infection)	C. difficile infection risk; hepatic considerations	Add for suspected GAS/clostridial infection.
Penicillin G	Adults: 2-4 million units IV Q4-6H (severe-infection dosing per protocol) Children and adolescents: 60,000-100,000 units/kg/dose Q6H IV (max 4 million units/dose)	Hypersensitivity; electrolyte load at high doses	Definitive therapy once GAS confirmed, with clindamycin.

MRSA and anaerobic coverage

Drug	Dosage	Adverse effects	Comments
Vancomycin	Adults: 1 g Q12H (or 15 mg/kg Q8-12H) IV, institutional AUC monitoring Children: 45-60 mg/kg/day divided Q6-8H IV	Nephrotoxicity, infusion reaction	Add empirically until MRSA is excluded.
Linezolid	Adults and children 12+: 600 mg IV/PO Q12H Infants and children under 12: 10 mg/kg/dose Q8H IV/PO (max 600 mg/dose)	Myelosuppression, serotonin syndrome, MAOI interactions	Selected severe Gram-positive infection under ID direction.<cite data-reference-id="a1916f47-12cd-4b78-b846-3e3020c0a76d"></cite>
Metronidazole	Adults: 500 mg IV/PO Q8-12H Children: 15-30 mg/kg/day divided Q8-12H (max 500 mg/dose; up to 1000 mg/dose in severe infection)	GI upset, neuropathy with prolonged therapy	Add when the broad regimen otherwise lacks anaerobic coverage.

References

Necrotizing soft-tissue infections — New England Journal of Medicine (Stevens DL, Bryant AE). N Engl J Med 2017;377(23):2253-2265
Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America — Clinical Infectious Diseases (Stevens DL, Bisno AL, Chambers HF, et al.). Clin Infect Dis 2014;59(2):e10-e52
Invasive Group A Streptococcal Disease — Guidelines for public health management — Public Health Agency of Canada. Public health guidance
Reserve list for antimicrobial drugs — Public Health Agency of Canada. Updated November 2024

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.